Health Sciences, Volume 23, Number 3(88) (2013)

A Single Center Experience in the Management Adverse Event in Heavily Pretreated Melanoma Patients in an Ipilimumab Expanded Access Programme at the Klaipeda University Hospital

Alvydas Česas, Asta Poškienė, Jolanta Česienė

Abstract


The incidence of metastatic melanoma has increased over the past three decades, and the death rate continues to rise faster than the rate with most cancers [1]. The survival rate for patients with metastatic melanoma is low, with an expected 2-year survival rate of 10 to 20%. Ipilimumab-immunotherapeutic, anti-CTLA4 monoclonal antibody drug, that has proven to be effective in inducing longlasting melanoma treatment response. Food and drug administration (FDA) has approved ipilimumab for patients with advanced melanoma in first and second- line treatment and European Medicines agency (EMA) for second- line melanoma treatment. The aim was to evaluate efficacy and safety of ipilimumab in metastatic or advanced melanoma treatment outside the clinical trials. Conclusion. Treatment with ipilimumab is well tolerated and safe. Imunerelated AE’s are risky to the patient, but early observed can be controlled without consequences.

 

 

doi:10.5200/sm-hs.2013.075


Keyword(s): ipilimumab, anti-CTLA4 monoconal antibody, immune-related AE, CTCAE v4

DOI: 10.5200/477

Full Text: PDF pdf